Posts tagged “Intersouth”
6fusion, which is backed by Intersouth partners, has raised $2 million in a mix of debt and options financing. The company hopes to raise $2 million more.
The company also strikes a deal to sell the firm after a future clinical trial to Janssen Biotech. Intersouth Partners, MPM lead the first round of financing for Vascular, which is focused on development of treatments for diabetes complications.
The venture capital backed startup, which has been funded locally by Intersouth Partners and NCIDEA, is commercializing technology developed at NC State.
With all the recent programs rolling out to support the launch and growth of new companies, funding remains scarce. If nothing else, lack of cash will keep a damper on entrepreneurs' hopes of flaming beyond control.
The biotechnology firm, backed by Intersouth Partners which is owed some $5 million, has been seeking to development treatments for hepatitis C. Biolex raised $60 million in 2008 in one of the state's biggest venture capital deals. It tried and failed to go public that same year.
The startup company's leading-edge solar technology "could soon make electricity cheaply enough to compete with power plants fueled by coal and natural gas," says the Massachusetts Institute for Technology in its annual "most important technology milestones" list.
The Durham-based drug development firm lands a new investor as well as more backing from Intersouth and Aurora Funds. The deal follows Argos' recent decision to terminate plans to go public.
Talk can be cheap, of course, and investors who look to Research Triangle Park have been pretty predictable over the years. But some new faces showed up at the CED Life Science Conference - and some familiar ones returned.
The Durham based venture capital-backed firm estimated an IPO price of between $13 and $15 per share. Some 5.25 million shares will be offered.
Aldagen, who had tried twice to go public only to withdraw both times amid poor market conditions, gets a partner interested in developing its stem cell treatments. Cytomedix gains prospective regenerative medicine therapies for its pipeline. But a payoff remains in the future and depends on drug trial results.
Regenerative medicine company Cytomedix has acquired the venture-capital backed company in a $16 million stock deal plus millions more in stock options. Aldagen investors include Intersouth and Aurora Funds.
The global provider of Ethernet related broadband services shortens its name, creates a new logo and revamps its websites. The changes come in the post-Hatteras Network merger, and among the recent moves is the departure of the former Hatteras CEO.
Cempra Pharmaceuticals sells 8.4 million shares at $6 each. The pricing had been expected to be higher.
Deal making totaled only $325 million across 47 deals, the lowest total since 2005 when one excludes the recession year of 2009. Life science deals dominate the fourth quarter.
The Chapel Hill-based company wants to sell 6 million shares at a price between $11 and $13 a share. Its underwriters have the right to sell another 900,000 shares.
- Britain's leaving the EU. What should I do with my money?
- No plan for layoffs, store closures as Southern Season restructures
- British brace for economic repercussions of EU exit decision
- Inventor with Duke connection seeks to subdue cellphone addiction
- Markets reel as world absorbs shock of UK vote for Brexit
- Women-led startups flex muscles at healthcare investment showcase
- Tech links: Epic v. Microsoft; Wilmington at Forbes; IBM blockchain; Arista-Cisco patent fight; IBM cloud foundation; GSK malaria vaccine
- Triangle headlines: RTI-Zika research; Quintiles glucose monitoring; Cree's LED plant lights; PatientPay exec; Q2 award